Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

12.06 -0.44 (-3.48%)

Streaming Delayed Price Updated: 2:25 PM EDT, Mar 18, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	457,090
Open	12.51
Bid (Size)	12.01 (100)
Ask (Size)	12.12 (300)
Prev. Close	12.50
Today's Range	11.92 - 12.70
52wk Range	11.21 - 50.40
Shares Outstanding	58,102,949
Dividend Yield	119.52%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

March 17, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

March 10, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-24.6%	-24.6%
1 Month	-7.5%	-7.5%
3 Month	-27.8%	-27.8%
6 Month	-70.8%	-70.8%
1 Year	-48.9%	-48.9%

More News

LENZ Therapeutics to Present at Upcoming Investor Conferences

February 23, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

January 14, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

January 07, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

January 05, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

December 01, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Present at Upcoming Investor Conferences

November 25, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q3 2025 Revenue Beat and Progress on VIZZ Launch ↗

November 05, 2025

Via Chartmill

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 05, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

October 29, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

September 30, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation

September 27, 2025

Via MarketMinute

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

August 25, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 11, 2025

Via Benzinga

Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket ↗

August 11, 2025

Via Benzinga

LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People ↗

August 01, 2025

Via Benzinga

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

July 31, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Lenz (LENZ) Q2 Revenue Jumps 604% ↗

July 31, 2025

Via The Motley Fool

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?

Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?

LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?

The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market

What is the current price of LENZ Therapeutics, Inc. - Common Stock?

The current price of LENZ Therapeutics, Inc. - Common Stock is 12.06

When was LENZ Therapeutics, Inc. - Common Stock last traded?

The last trade of LENZ Therapeutics, Inc. - Common Stock was at 03/18/26 02:25 PM ET

What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?

The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 701.01M

How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?

LENZ Therapeutics, Inc. - Common Stock has 701M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.